Evofem Biosciences, Inc. EVFM

Company Overview

Evofem Biosciences, Inc. is a biotechnology and commercial-stage women’s health company focused on developing and commercializing non-hormonal reproductive health products. The company has primarily operated in the prescription contraceptive and sexually transmitted infection prevention markets, with its flagship commercial product being Phexxi, a non-hormonal, on-demand prescription contraceptive vaginal gel approved in the United States. Evofem has positioned itself within the broader biopharmaceutical and women’s healthcare industries by emphasizing alternatives to hormonal contraceptive methods and expanding access to reproductive health solutions.

The company evolved from earlier biotechnology operations and later refocused its strategy toward women’s reproductive healthcare through product development, licensing arrangements, and commercialization efforts centered on Phexxi. Public filings and corporate disclosures indicate that Evofem’s business strategy historically relied heavily on commercialization partnerships, prescription growth, reimbursement expansion, and women’s health advocacy initiatives. The company’s market positioning has been tied to serving patients seeking non-hormonal contraceptive options and healthcare providers specializing in gynecology, reproductive medicine, and women’s wellness.